ALB and cancer: However, hepatic dysfunction marked by elevated AST/ALT ratio (HR: 1.20, 95% CI: 1.05–1.36, p = 0.007) and metabolic disturbances including lower triglycerides, higher glycated albumin, and reduced lymphocytes were associated with cancer risk (all p < 0.05; Table 2), requiring further validation.